Haina Pharma Completes RMB 100 Million Financing Round to Build a Leading Domestic Integrated CXO+MAH Platform

VCBeat has learned that Nanjing Haina Medical Technology Co., Ltd. (“Haina Medical”) completed a new round of equity financing in August 2022. The round was led by CICC Transfar Fund, under CICC Capital, with participation from Shanlan Capital, Jiangxi Provincial State-owned Industrial Development Fund, and other investors. The proceeds will be used entirely for expanding the R&D pipeline and enlarging the R&D team.

Nanjing Haina Medical Technology Co.,Ltd. was established in 2001. It is a pharmaceutical R&D group enterprise characterized by being R&D-driven, innovation-oriented, and continuously advancing the acquisition of new product portfolios.and gradually formed a business model driven by the dual engines of “CXO + MAH.”Currently, Nanjing Haina Medical Technology Co.,Ltd. holds marketing authorizations for more than 20 products, has over 60 projects under review or in development, and has provided more than 500 professional services, including CRO and CDMO, to over 100 domestic partner clients.The number of product submissions and the approval rate for our company’s products rank among the top in the national industry, with a zero rejection rate due to technical reasons.

In terms of core technologies, leveraging the advantages of its integrated end-to-end process, Nanjing Haina Medical Technology Co., Ltd. has focused on building core technology platforms, including a chiral drug directional synthesis and resolution platform, an advanced formulation technology platform combining imitation and innovation, and a quality research technology platform. With the goal of securing product approvals, the company continuously promotes the efficient translation of R&D achievements. Meanwhile, the company operates production workshops for more than 10 dosage forms, including oral solid preparations, oral liquid preparations, injections, micro-pills, gels, and gel patches. Adhering to the quality philosophy of “Quality First,” it is committed to building a comprehensive pharmaceutical and health industry.

Zou Qiaogen, Founder and Chairman of the Board, stated, “We sincerely thank both new and existing investors for their trust and support in Haina. With over two decades of deep engagement in the pharmaceutical R&D industry, Haina Medical boasts robust pharmaceutical research and development capabilities and a strong reputation within the industry. In recent years, an increasing number of our independently initiated drug candidates have received regulatory approval. Looking ahead, we will continue to tap into our potential, uphold the spirit of craftsmanship, and deliver high-quality end-to-end services backed by solid technical expertise, striving to become a leading benchmark enterprise in the industry.”

Tong Xuanzi, head of the CICC Transfar Fund, stated, “In light of the continuous optimization and improvement of China’s regulatory approval system, the importance of CROs within the pharmaceutical industry chain is increasingly prominent. The CICC Transfar Fund supports and is optimistic about the company’s integrated ‘CXO+MAH’ full-process business model. With a robust R&D pipeline and sustained high-speed performance growth, we believe that Nanjing Haina Medical Technology Co., Ltd. will leverage its advanced and solid R&D technical capabilities and end-to-end service advantages to lead the development of drug R&D in China toward greater professionalism and efficiency.”

The CICC Transfar Industrial Equity Investment Fund, jointly initiated by CICC Capital and Transfar Group, primarily targets emerging industries such as healthcare, high-end manufacturing, and new materials, with an initial size of RMB 3 billion. The fund will fully leverage CICC Capital’s professional expertise in equity investment management, along with its superior platform and resource advantages, while combining Transfar Group’s long-standing cultivation and leading position in related industrial sectors to actively identify high-quality projects with high growth potential. Through sophisticated market-oriented operations, strong industrial integration capabilities, and comprehensive financial support services, the fund aims to strengthen the integration of industry and finance, thereby empowering its portfolio investments.

Shanlan Capital is a professional fund dedicated to early-stage investments in the healthcare industry, focusing on high-growth segments such as innovative medical devices (in vitro diagnostics and gene technologies, minimally invasive interventions, implantable devices, minimally invasive surgical instruments, and medical robotics), innovative biopharmaceuticals, life sciences, and healthcare services. The firm has invested in nearly 50 star enterprises in the medical and pharmaceutical sectors, including Guoke Hengtai, Nanjing Haina Medical Technology Co., Ltd., Deepwise Healthcare, Shengshi Taike, Baichen Medical, Zhishan Medical, Qianglian Zhichuang, Weike Medical, Ligatai, Langhe Medical, and Puqi Pharmaceuticals. Shanlan Capital’s core team comprises founders of publicly listed healthcare companies, as well as professionals specializing in the medical and pharmaceutical industries, finance, and strategic investment. The firm provides value-added services to its portfolio companies in areas such as strategy formulation, talent acquisition, R&D, marketing, legal and regulatory compliance, mergers and acquisitions, IPOs, and industry association resources. It also assists portfolio companies in integrating advanced international technologies and establishing international operational concepts and standards, thereby fostering continuous innovation and development.